Becton Dickinson & CO BDX
We take great care to ensure that the data presented and summarized in this overview for BECTON DICKINSON & CO is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding BDX
View all-
Vanguard Group Inc Valley Forge, PA26.6MShares$5.94 Billion0.12% of portfolio
-
Black Rock Inc. New York, NY22.3MShares$4.98 Billion0.12% of portfolio
-
State Street Corp Boston, MA14MShares$3.12 Billion0.14% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD13.6MShares$3.04 Billion0.38% of portfolio
-
Morgan Stanley New York, NY11MShares$2.46 Billion0.2% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD8.91MShares$1.99 Billion1.3% of portfolio
-
Geode Capital Management, LLC Boston, MA6.29MShares$1.41 Billion0.12% of portfolio
-
Generation Investment Management LLP London, X05.95MShares$1.33 Billion6.87% of portfolio
-
Massachusetts Financial Services CO Boston, MA5.37MShares$1.2 Billion0.4% of portfolio
-
Jpmorgan Chase & CO New York, NY4.02MShares$899 Million0.08% of portfolio
Latest Institutional Activity in BDX
Top Purchases
Top Sells
About BDX
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.
Insider Transactions at BDX
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Dec 19
2024
|
Michael David Garrison EVP & President, Medical |
SELL
Open market or private sale
|
Direct |
2,838
-31.61%
|
$632,874
$223.33 P/Share
|
Dec 09
2024
|
Roland Goette EVP and President, EMEA |
SELL
Open market or private sale
|
Direct |
638
-4.29%
|
$139,722
$219.03 P/Share
|
Dec 06
2024
|
Roland Goette EVP and President, EMEA |
SELL
Sale (or disposition) back to the issuer
|
Direct |
9,490
-38.98%
|
$2,097,290
$221.01 P/Share
|
Dec 06
2024
|
Roland Goette EVP and President, EMEA |
SELL
Open market or private sale
|
Direct |
4,483
-15.55%
|
$990,743
$221.01 P/Share
|
Dec 06
2024
|
Roland Goette EVP and President, EMEA |
BUY
Exercise of conversion of derivative security
|
Direct |
13,334
+20.88%
|
$2,093,438
$157.79 P/Share
|
Dec 06
2024
|
Shana Carol Neal EVP and Chief People Officer |
SELL
Open market or private sale
|
Direct |
1,000
-5.56%
|
$220,000
$220.49 P/Share
|
Dec 05
2024
|
David Shan EVP and Chief ISC Officer |
SELL
Open market or private sale
|
Direct |
1,500
-19.27%
|
$330,000
$220.25 P/Share
|
Nov 26
2024
|
Pavan Kumar Mocherla EVP & President Greater Asia |
SELL
Payment of exercise price or tax liability
|
Direct |
20
-0.7%
|
-
|
Nov 26
2024
|
Pavan Kumar Mocherla EVP & President Greater Asia |
BUY
Grant, award, or other acquisition
|
Direct |
1,055
+15.21%
|
-
|
Nov 26
2024
|
Michelle Quinn EVP and General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
376
-5.15%
|
-
|
Nov 26
2024
|
Michelle Quinn EVP and General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
2,348
+13.65%
|
-
|
Nov 26
2024
|
Shana Carol Neal EVP and Chief People Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
509
-2.75%
|
-
|
Nov 26
2024
|
Shana Carol Neal EVP and Chief People Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,109
+10.23%
|
-
|
Nov 26
2024
|
Michael Feld EVP & President, Life Sciences |
BUY
Grant, award, or other acquisition
|
Direct |
2,553
+21.74%
|
-
|
Nov 26
2024
|
Antoine C Ezell EVP, President Americas & CMO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,357
-10.18%
|
-
|
Nov 26
2024
|
Antoine C Ezell EVP, President Americas & CMO |
BUY
Grant, award, or other acquisition
|
Direct |
4,007
+13.95%
|
-
|
Nov 26
2024
|
Christopher Del Orefice EVP & Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,192
-19.45%
|
-
|
Nov 26
2024
|
Christopher Del Orefice EVP & Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
13,899
+23.45%
|
-
|
Nov 26
2024
|
Richard Byrd EVP & President Interventional |
SELL
Payment of exercise price or tax liability
|
Direct |
1,204
-11.41%
|
-
|
Nov 26
2024
|
Richard Byrd EVP & President Interventional |
BUY
Grant, award, or other acquisition
|
Direct |
4,495
+19.44%
|
-
|
Last 12 Months Summary
Grant, award, or other acquisition | 108K shares |
---|---|
Exercise of conversion of derivative security | 18.6K shares |
Payment of exercise price or tax liability | 37.2K shares |
---|---|
Open market or private sale | 19.4K shares |
Sale (or disposition) back to the issuer | 13.5K shares |